Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ovarian Clear Cell Cystadenocarcinoma: early-phase trial registry
A small indexed set (5 trials) with no open enrollment listed right now.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · none currently recruiting · #3,391 of 28,707 conditions by registered trial count
Ovarian Clear Cell Cystadenocarcinoma: 5 US clinical trials tracked, none currently recruiting.
Ovarian Clear Cell Cystadenocarcinoma is the subject of 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition ovarian-clear-cell-cystadenocarcinoma
OPEN 0 | RECR 0% | LATE 0 | EARLY 5 | RANK #3391 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Ovarian Clear Cell Cystadenocarcinoma has no open enrollment in this registry pull (5 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ovarian Clear Cell Cystadenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ovarian Clear Cell Cystadenocarcinoma is recruiting below its size-band peers.
0 of 5 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Ovarian Clear Cell Cystadenocarcinoma research.
National Cancer Institute (NCI) accounts for 3 of 5 trials (60%). 3 distinct sponsors appear on at least one study for this condition label.
-
Most Ovarian Clear Cell Cystadenocarcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Ovarian Clear Cell Cystadenocarcinoma research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
National Cancer Institute (NCI)
NCT02101775
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
NCT02122185
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
National Cancer Institute (NCI)
NCT02142803
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Gynecologic Oncology Group
NCT00939809
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
National Cancer Institute (NCI)
NCT00993616
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Ovarian Clear Cell Cystadenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ovarian Clear Cell Cystadenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ovarian Clear Cell Cystadenocarcinoma page
5 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Ovarian Clear Cell Cystadenocarcinoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Ovarian Clear Cell Cystadenocarcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ovarian Clear Cell Cystadenocarcinoma condition card totals 5 registered trials; most-linked intervention Laboratory Biomarker Analysis; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.